-
-
-
-
-
-
-
Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures
-
-
-
-
-
-
-
Melinta Therapeutics (MLNT) Reports FDA Approval of Supplemental NDA for BAXDELA (delafloxacin) for Treatment of CABP
-
-
-
-
-
-
-
Melinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan
-
-
-
-
-
-
-
Melinta Therapeutics Announces Preliminary Second Quarter 2019 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting
-
-
-
-
-
-
-
After-Hours Movers 03/13: (SMSI) (IDSY) (MDB) Higher; (TLRD) (CLDR) (AXGT) (more...)
-
-
-
-
-
-
-
Melinta Therapeutics (MLNT) Board Approves 1-for-5 Reverse Stock Split
-
1,157,743 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

